ATE367802T1 - Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat - Google Patents

Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Info

Publication number
ATE367802T1
ATE367802T1 AT01937182T AT01937182T ATE367802T1 AT E367802 T1 ATE367802 T1 AT E367802T1 AT 01937182 T AT01937182 T AT 01937182T AT 01937182 T AT01937182 T AT 01937182T AT E367802 T1 ATE367802 T1 AT E367802T1
Authority
AT
Austria
Prior art keywords
fenofibrate
spray drying
compositions containing
powdered compositions
dosage forms
Prior art date
Application number
AT01937182T
Other languages
English (en)
Inventor
Gary Pace
Awadhesh Mishra
Robert Snow
Indu Parikh
H Pol-Henri Dr Guivarc
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE367802T1 publication Critical patent/ATE367802T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01937182T 2000-09-20 2001-04-20 Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat ATE367802T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23418600P 2000-09-20 2000-09-20
US24176100P 2000-10-20 2000-10-20
US27015701P 2001-02-22 2001-02-22

Publications (1)

Publication Number Publication Date
ATE367802T1 true ATE367802T1 (de) 2007-08-15

Family

ID=27398528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01937182T ATE367802T1 (de) 2000-09-20 2001-04-20 Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat

Country Status (9)

Country Link
US (1) US6696084B2 (de)
EP (1) EP1322289B1 (de)
AT (1) ATE367802T1 (de)
AU (2) AU6294501A (de)
CA (1) CA2423335C (de)
DE (1) DE60129573T2 (de)
NZ (1) NZ525306A (de)
TW (1) TWI293877B (de)
WO (1) WO2002024169A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US6182712B1 (en) 1997-07-21 2001-02-06 Inhale Therapeutic Systems Power filling apparatus and methods for their use
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
HUP0105089A3 (en) * 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003088951A1 (en) * 2002-04-15 2003-10-30 Eiffel Technologies Limited Formulation of fine particles using liquefied or dense gases
NO346970B1 (no) * 2002-05-24 2023-03-20 Alkermes Pharma Ireland Ltd Nanopartikulære fiberformuleringer
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
JP4831965B2 (ja) * 2002-06-10 2011-12-07 エラン ファーマ インターナショナル,リミティド HMG−CoA還元酵素インヒビター誘導体(「スタチン」)を含むナノ粒子製剤、その新規組合せ、ならびにこれらの医薬組成物の製造
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
WO2004002827A1 (en) * 2002-06-27 2004-01-08 Nektar Therapeutics Device and method for controlling the flow of a powder
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
EP1631496B1 (de) 2003-04-28 2014-02-26 Medical Instill Technologies, Inc. Behälter mit ventilanordnung zum füllen und abgeben von stoffen und vorrichtung und verfahren zum füllen
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
MXPA06003813A (es) * 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
KR20130103818A (ko) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
CA2543596A1 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US7611630B2 (en) * 2004-03-30 2009-11-03 Bend Research, Inc. Method and device for evaluation of pharmaceutical compositions
CN1933816A (zh) * 2004-03-30 2007-03-21 史密丝克莱恩比彻姆公司 喷雾干燥的药物组合物
US7101585B2 (en) * 2004-04-15 2006-09-05 Solae, Llc Ultra high pressure homogenization process for making a stable protein based acid beverage
US7306562B1 (en) * 2004-04-23 2007-12-11 Medical Software, Llc Medical risk assessment method and program product
GB0411502D0 (en) * 2004-05-22 2004-06-23 Britannia Pharmaceuticals Ltd Pharmaceutical compositions
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057216A1 (en) * 2004-09-15 2006-03-16 Salamone Joseph C Low-obscuration image transmitting particulate ocular therapeutic formulations
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
CA2582403A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
WO2006037345A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical composition comprising fenofibrate and simvastatin
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
BRPI0606883A2 (pt) * 2005-02-10 2009-12-01 Lifecycle Pharma As composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin
MX2007012124A (es) * 2005-03-30 2007-11-21 Teva Pharma Formulaciones mejoradas de fenofibrato.
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
MX2007011858A (es) * 2005-03-30 2008-03-25 Teva Pharma Formulaciones mejoradas de fenofibrato que contienen mentol o peg/poloxamero.
WO2006084475A2 (en) * 2005-04-13 2006-08-17 Lifecycle Pharma A/S A tablet comprising a fibrate
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
CA2628666A1 (en) * 2005-11-21 2007-05-24 Teva Pharmaceutical Industries Ltd. Atorvastatin formulation
EP1808162A1 (de) * 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Pharmazeutische Formulierung von Atorvastatin
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
PL1803441T3 (pl) * 2005-12-28 2009-10-30 Teva Pharma Farmaceutyczne formulacje fenofibratu o polepszonej biodostępności
CA2634094A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
WO2007100609A2 (en) * 2006-02-24 2007-09-07 Albert Einstein College Of Medicine Of Yeshiva University Electron transfer through glassy matrices
JP5566101B2 (ja) 2006-04-24 2014-08-06 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 針貫通可能かつレーザ再密閉可能な凍結乾燥装置およびこれに関連する方法
EP1870649A1 (de) 2006-06-20 2007-12-26 Octapharma AG Gefriertocknung zum Erzielen einer bestimmte Restfeuchte durch beschränkte Desorptionsenergiepegeln.
US7877895B2 (en) 2006-06-26 2011-02-01 Tokyo Electron Limited Substrate processing apparatus
MX2009000035A (es) * 2006-06-26 2009-05-28 Mutual Pharmaceutical Co Formulaciones de agente activo, procedimientos de preparacion y procedimientos de uso.
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
SI2046292T1 (sl) * 2006-07-21 2010-06-30 Novartis Ag Formulacije za benzimidazolil piridil etre
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US7908765B2 (en) * 2006-12-22 2011-03-22 Collette Nv Continuous granulating and drying apparatus
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
US8974827B2 (en) * 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
EP2240162A4 (de) * 2007-12-06 2013-10-09 Bend Res Inc Nanoteilchen mit einem nicht-ionisierbaren polymer und einem amin-funktionalisierten methacrylat-copolymer
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US20090182053A1 (en) * 2007-12-19 2009-07-16 Tong Sun Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
JP2012523414A (ja) 2009-04-09 2012-10-04 エンテグリオン、インコーポレイテッド 噴霧乾燥した血液製剤とその製造方法
US20110142885A1 (en) 2009-09-16 2011-06-16 Velico Medical, Inc. Spray-dried human plasma
KR100980749B1 (ko) 2009-12-17 2010-09-07 삼일제약주식회사 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2618924A1 (de) 2010-09-24 2013-07-31 Bend Research, Inc. Hochtemperatur-sprühtrocknungsverfahren und verfahren
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
BR112014025518B1 (pt) 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
MX2013006332A (es) * 2013-06-05 2014-12-19 Alparis Sa De Cv Composiciones farmaceuticas orales para uso en dislipidemias.
EP2878311A1 (de) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
PL3154528T3 (pl) 2014-06-11 2023-07-10 SpecGx LLC Suszone rozpyłowo kompozycje o różnych profilach rozpuszczania i sposoby ich wytwarzania
US9561184B2 (en) 2014-09-19 2017-02-07 Velico Medical, Inc. Methods and systems for multi-stage drying of plasma
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR102883123B1 (ko) 2015-06-22 2025-11-10 아레나 파마슈티칼스, 인크. S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US10627161B2 (en) * 2018-01-24 2020-04-21 King Abdulaziz City for Science and Technology (KACST) Laboratory equipment and method of using the same for drying a starting material to produce nano material
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
WO2022183281A1 (en) * 2021-03-03 2022-09-09 Mcmaster Christopher R Compounds and treatments for muscular dystrophy
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
WO2024059770A1 (en) 2022-09-15 2024-03-21 Velico Medical, Inc. Rapid spray drying system
US11998861B2 (en) 2022-09-15 2024-06-04 Velico Medical, Inc. Usability of a disposable for a spray drying plasma system
US12083447B2 (en) 2022-09-15 2024-09-10 Velico Medical, Inc. Alignment of a disposable for a spray drying plasma system
US12246093B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Methods for making spray dried plasma
US12246266B2 (en) 2022-09-15 2025-03-11 Velico Medical, Inc. Disposable for a spray drying system
US11975274B2 (en) 2022-09-15 2024-05-07 Velico Medical, Inc. Blood plasma product
US11841189B1 (en) 2022-09-15 2023-12-12 Velico Medical, Inc. Disposable for a spray drying system
US20240131236A1 (en) * 2022-09-15 2024-04-25 Velico Medical, Inc. Dryer For A Spray Drying System

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329446A1 (de) 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
DE69728206T2 (de) 1996-05-14 2005-03-10 Dsm Ip Assets B.V. Herstellungsverfahren für Carotenoid-Zusammensetzungen
CZ299790B6 (cs) * 1996-08-22 2008-11-26 Skyepharma Canada Inc. Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic
HUP0105089A3 (en) * 1998-11-20 2002-09-30 Skyepharma Canada Inc Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten

Also Published As

Publication number Publication date
EP1322289B1 (de) 2007-07-25
US20020056206A1 (en) 2002-05-16
US6696084B2 (en) 2004-02-24
AU2001262945B2 (en) 2006-02-02
CA2423335C (en) 2011-03-01
CA2423335A1 (en) 2002-03-28
TWI293877B (en) 2008-03-01
EP1322289A1 (de) 2003-07-02
DE60129573T2 (de) 2008-04-17
AU6294501A (en) 2002-04-02
DE60129573D1 (de) 2007-09-06
WO2002024169A1 (en) 2002-03-28
NZ525306A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
ATE367802T1 (de) Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
KR100757155B1 (ko) 저용량의 엔테카비르 제제 및 그의 용도
EA029890B1 (ru) Фармацевтическая композиция и фармацевтическая композиция в пероральной дозированной лекарственной форме на основе ингибитора dpp iv
DK1094788T3 (da) Smagsmaskering med croscarmellose
CA2874779C (en) Pharmaceutical composition of entecavir and process of manufacturing
NO20011211D0 (no) Multippel enhet for kontrollert mateffektuavhengig frigivelse av farmasøytiske preparater og fremgangsmÕter for fremstilling av samme
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
RU2002123182A (ru) Содержащая ибупрофен композиция
MXPA04003346A (es) Formulacion de dosis oral de disolucion instantanea.
JP5674275B2 (ja) 活性成分の放出時間が長い組成物、その調製方法および利用方法
RU2199312C1 (ru) Способ получения лекарственных средств из растительных экстрактов в твердой форме
RU2287338C2 (ru) Способ получения таблеток из сухого экстракта зверобоя
RU2188017C1 (ru) Способ получения таблеток комбинированного препарата триметоприма с сульфаметоксазолом
AU2006235960B2 (en) Low dose entecavir formulation and use
EP3900708A1 (de) Zaltoprofen enthaltendes arzneimittel mit verzögerter freisetzung
EP1013271A2 (de) Tabletten enthaltend Nimodipin
NZ533283A (en) High-dosage nelfinavir tablet comprising nelfinavir mesylate in an amount of up to 730 mg
RU2190403C1 (ru) Фармацевтическая композиция, обладающая антибактериальным действием, и способ ее получения
KR20010089479A (ko) 식물 추출물로부터 고체 투여 형태의 약제를 제조하는 방법
AU2003239460A1 (en) Increased-dosage nelfinavir tablet and method of making same
MXPA99009580A (en) Procedure for preparing pharmaceutical programmed release compositions containing nipodim

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties